{
    "clinical_study": {
        "@rank": "159757", 
        "arm_group": [
            {
                "arm_group_label": "sorafenib", 
                "arm_group_type": "Active Comparator", 
                "description": "800 mg of sorafenib twice daily orally."
            }, 
            {
                "arm_group_label": "sorafenib-pravastatin", 
                "arm_group_type": "Experimental", 
                "description": "800 mg of sorafenib twice daily oral doses associated with 40 mg of pravastatin in a taken per os. Pravastatin will be taken during dinner."
            }
        ], 
        "brief_summary": {
            "textblock": "Principal objective: to evaluate the effect of the combination pravastatin - sorafenib\n      versus sorafenib alone on overall survival in patients with hepatocellular carcinoma\n      developing on Child-Pugh A cirrhosis who are unsuitable for curative treatment.\n\n      Secondary objectives: evaluate the effect of this treatment on progression-free survival,\n      the time to progression, the time to treatment failure and quality of life (QLQ-C30 et FACT\n      HEP)"
        }, 
        "brief_title": "Randomized Trial Sorafenib-Pravastatin Versus Sorafenib Alone for the Palliative Treatment of Child-Pugh A Hepatocellular Carcinoma", 
        "condition": "Child-Pugh A Hepatocellular Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Hepatocellular"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Hepatocellular carcinoma diagnosed by:\n\n          -  either a histological examination\n\n          -  or if histological evidence cannot be obtained (ascites, coagulation disorders) the\n             diagnosis can be made in cases of cirrhosis according to EASL/AASLD 2005 criteria, by\n             revealing a hepatic focal lesion of more than 10 mm\n\n          -  on two dynamic imaging techniques (helical CT-scan, MRI, contrast-enhanced\n             ultrasound) for tumours measuring less than 2 cm. The lesion must be characterised by\n             hyperdensity during the arterial phase and wash-out during the delayed portal phase\n             Patients who are not suitable for treatment with a curative intent (transplantation,\n             resection, percutaneous destruction) or by chemo-embolisation or with progressive\n             hepatocellular carcinoma after the failure of specific treatment Prognostic CLIP\n             score 0 to 4 Child-Pugh Class A Transaminases \u2264 5 N and Creatininemia \u2264 1.5 N WHO: 0,\n             1 or 2 Age more than 18 years Foreseeable survival > 12 weeks Possibility of regular\n             follow-up Written informed consent\n\n        Exclusion Criteria:\n\n          -  Extra-hepatic disease that could be life-threatening in the short or medium term\n             Another progressive cancer with the exception of in situ cervical cancer, a\n             superficial bladder tumour and treated basocellular carcinoma.\n\n        Any other cancer treated with a curative intent in the previous 3 years can be included in\n        the study Heart failure (\u2265New York Heart Association class 2), uncontrolled AHT or\n        arrhythmia, myocardial infarction in the previous 6 months Digestive haemorrhage in the\n        previous month Patients who are receiving or have already received treatment with statins\n        or sorafenib Pregnancy and breast-feeding. Women of child-bearing age must use an\n        effective method of contraception throughout the trial and for 3 months after the end of\n        the treatment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "474", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01903694", 
            "org_study_id": "JOUVE PHRC K 2009"
        }, 
        "intervention": [
            {
                "arm_group_label": "sorafenib-pravastatin", 
                "intervention_name": "Sorafenib + Pravastatin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "800 mg of sorafenib twice daily oral doses associated with", 
                    "40 mg of pravastatin in a taken per os. Pravastatin will be taken during dinner."
                ]
            }, 
            {
                "arm_group_label": "sorafenib", 
                "intervention_name": "Sorafenib", 
                "intervention_type": "Drug", 
                "other_name": "800 mg of sorafenib twice daily orally."
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Pravastatin", 
                "Sorafenib"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 12, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Dijon", 
                    "country": "France", 
                    "zip": "21079"
                }, 
                "name": "CHU de Dijon"
            }
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "France: Afssaps - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Saint-Denis)"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "determination of the tumor according to the evaluation criteria of Response Evaluation Criteria in Solid Tumors", 
            "safety_issue": "No", 
            "time_frame": "To be done within the month preceding baseline"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01903694"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Centre Hospitalier Universitaire Dijon", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Centre Hospitalier Universitaire Dijon", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}